Linked Life Data

19754390

Source:http://linkedlifedata.com/resource/pubmed/id/19754390

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
27
pubmed:dateCreated
2009-9-16
pubmed:abstractText
Type 2 diabetes is associated with substantially increased cardiovascular mortality. The need to reduce the progression of atherosclerosis alongside lowering blood glucose levels is now well established. Ideally, pharmaceutical treatment should address both of these needs. This review summarises current evidence of the anti-atherosclerotic effects exerted by oral antidiabetic agents. Metformin has so far consistently succeeded in reducing cardiovascular morbidity and mortality and exerting beneficial effects on lipids. Of the new agents, thiazolidinediones (rosiglitazone and pioglitazone) have been most widely studied. They have a favourable effect on fat distribution and improve lipid profile, fibrinolysis and endothelial function. Moreover, they reduce blood pressure and inflammatory markers, attenuate the progression of carotid intima-media thickness (CIMT) and may reduce the rates of coronary restenosis following percutaneous coronary intervention. Glinides (repaglinide and nateglinide) have also been documented to improve endothelial function and lipid profile, to reduce oxidative stress, platelet activity and inflammatory markers, and to diminish the progression of CIMT. Finally, acarbose may significantly reduce new cases of hypertension and cardiovascular events, as well as diminishing the progression of CIMT in patients with impaired glucose tolerance. Interestingly, some of these beneficial effects appear to be independent of the antidiabetic action. Thus, oral antidiabetic agents are now emerging as useful tools for the attenuation of the atherosclerotic activity and for the protection of the vasculature in patients with type 2 diabetes.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1873-4286
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
15
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
3179-92
pubmed:meshHeading
pubmed-meshheading:19754390-Acarbose, pubmed-meshheading:19754390-Administration, Oral, pubmed-meshheading:19754390-Animals, pubmed-meshheading:19754390-Atherosclerosis, pubmed-meshheading:19754390-Biological Markers, pubmed-meshheading:19754390-Blood Glucose, pubmed-meshheading:19754390-Cardiovascular Diseases, pubmed-meshheading:19754390-Diabetes Mellitus, Type 2, pubmed-meshheading:19754390-Evidence-Based Medicine, pubmed-meshheading:19754390-Humans, pubmed-meshheading:19754390-Hypoglycemic Agents, pubmed-meshheading:19754390-Lipids, pubmed-meshheading:19754390-Metformin, pubmed-meshheading:19754390-Patient Selection, pubmed-meshheading:19754390-Risk Assessment, pubmed-meshheading:19754390-Sulfonylurea Compounds, pubmed-meshheading:19754390-Thiazolidinediones, pubmed-meshheading:19754390-Treatment Outcome
pubmed:year
2009
pubmed:articleTitle
Oral antidiabetic agents: anti-atherosclerotic properties beyond glucose lowering?
pubmed:affiliation
Outpatient Clinic of Obesity, Diabetes and Metabolism at the Second Department of Internal Medicine, Democritus University of Thrace, Greece. papanasnikos@yahoo.gr
pubmed:publicationType
Journal Article, Review